calcium polystyrene sulfonate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4871	37286-92-3

Description:

Molecule

Description

Synonyms:

calcium polystyrene sulfonate
calcium polystyrene sulphonate
calcium polystyrenesulfonate
kalimate

Molecular weight:
Formula: (C16H14CaO6S2)n
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
45	g	O

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Renal impairment	64.71	35.26	31	1050	88324	63399617
Cardiac failure	55.46	35.26	28	1053	89114	63398827
Hyperkalaemia	52.11	35.26	23	1058	54180	63433761
Shunt stenosis	39.48	35.26	7	1074	533	63487408
Shunt occlusion	38.02	35.26	7	1074	658	63487283

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperkalaemia	83.95	25.42	51	1940	69338	34885602
Crystal deposit intestine	78.63	25.42	12	1979	99	34954841
Renal impairment	47.95	25.42	41	1950	94472	34860468
Shunt stenosis	33.59	25.42	8	1983	774	34954166
Cardiac failure	29.73	25.42	31	1960	91217	34863723
Interstitial lung disease	26.47	25.42	25	1966	65257	34889683
Hepatic function abnormal	26.08	25.42	21	1970	44342	34910598

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperkalaemia	126.63	28.06	71	3231	114327	79626759
Renal impairment	103.16	28.06	70	3232	157713	79583373
Crystal deposit intestine	81.00	28.06	13	3289	215	79740871
Cardiac failure	72.15	28.06	56	3246	154786	79586300
Shunt stenosis	68.53	28.06	15	3287	1376	79739710
Hepatic function abnormal	51.41	28.06	34	3268	73073	79668013
Anaemia	42.26	28.06	70	3232	444945	79296141
Interstitial lung disease	40.36	28.06	35	3267	112565	79628521
Acute kidney injury	36.89	28.06	72	3230	519332	79221754
Shunt occlusion	35.84	28.06	9	3293	1495	79739591
Chronic kidney disease	35.33	28.06	26	3276	66128	79674958

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V03AE01	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Drugs for treatment of hyperkalemia and hyperphosphatemia
MeSH PA	D002411	Cation Exchange Resins
MeSH PA	D002614	Chelating Agents
MeSH PA	D007475	Ion Exchange Resins
MeSH PA	D064449	Sequestering Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hyperkalemia	indication	14140009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
HUI2S00793	UNII
D03270	KEGG_DRUG
C0108139	UMLSCUI
CHEBI:53277	CHEBI
CHEMBL2109033	ChEMBL_ID
C003321	MESH_SUPPLEMENTAL_RECORD_UI
DB01344	DRUGBANK_ID
1546437	RXNORM
003509	NDDF
006664	NDDF
1002242008	SNOMEDCT_US
395788004	SNOMEDCT_US
710808009	SNOMEDCT_US
C0137904	UMLSCUI
CHEMBL1201484	ChEMBL_ID
8324	INN_ID
28210-41-5	SECONDARY_CAS_RN
169893	PUBCHEM_CID
58817179	PUBCHEM_CID
ZSL2FB6GXN	UNII

Pharmaceutical products:

None